한빛사
>
한빛사논문
한빛사논문
- 조회36
Coord. Chem. Rev., Available online 5 May 2025 | https://doi.org/10.1016/j.ccr.2025.216767
Liquid biopsy for cancer immunotherapy: Biomarkers to predict and monitor response upon immune checkpoint blockade
Chae Yeon Son a,1, Deborah Lee a,b,1, Hyun Sung Park a, Jung Hyun Choi a,c, Dong Hyung Kim c, Il Doh c, Lifeng Kang b, Jiyoon Bu a,d, Sun Min Kim a,d,e, Tae-Joon Jeon a,b,d
aDepartment of Biological Sciences and Bioengineering, Inha University, 100 Inha-ro, Michuhol-gu, Incheon 22212, Republic of Korea
bSchool of Pharmacy, Faculty of Medicine and Health, University of Sydney, Pharmacy and Bank Building A15, NSW 2006, Australia
cDivision of Advanced Instrumentation Institute, Korea Research Institute of Standards and Science (KRISS), 267 Gajeongno, Yuseong-Gu, Daejeon 34113, Republic of Korea
dBiohybrid Systems Research Center, Inha University, 100 Inha-ro, Michuhol-gu, Incheon 22212, Republic of Korea
eDepartment of Mechanical Engineering, Inha University, 100 Inha-ro, Michuhol-gu, Incheon 22212, Republic of Korea
1Both authors contributed equally to this work.
Corresponding authors : Jiyoon Bu, Sun Min Kim, Tae-Joon Jeon
aDepartment of Biological Sciences and Bioengineering, Inha University, 100 Inha-ro, Michuhol-gu, Incheon 22212, Republic of Korea
bSchool of Pharmacy, Faculty of Medicine and Health, University of Sydney, Pharmacy and Bank Building A15, NSW 2006, Australia
cDivision of Advanced Instrumentation Institute, Korea Research Institute of Standards and Science (KRISS), 267 Gajeongno, Yuseong-Gu, Daejeon 34113, Republic of Korea
dBiohybrid Systems Research Center, Inha University, 100 Inha-ro, Michuhol-gu, Incheon 22212, Republic of Korea
eDepartment of Mechanical Engineering, Inha University, 100 Inha-ro, Michuhol-gu, Incheon 22212, Republic of Korea
1Both authors contributed equally to this work.
Corresponding authors : Jiyoon Bu, Sun Min Kim, Tae-Joon Jeon
Abstract
Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has revolutionized cancer treatment, offering durable responses in a specific subset of patients. However, the lack of reliable indicators or monitoring methods to estimate ICI efficacy remains a significant challenge. Various liquid biopsy assays have emerged as promising tools to overcome these limitations due to their non-invasive nature and ability to capture tumor heterogeneity. This review provides a systematic and comprehensive overview of clinical studies, categorizing liquid biopsy biomarkers—including ctDNA, CTCs, soluble proteins, and exosomes—based on their clinical applications and presenting specific, detailed findings from the most up-to-date research. Additionally, this review addresses the limitations of each biomarker, as highlighted by conflicting results in some clinical studies, and explores prospects for overcoming these challenges through advanced technologies and integrated approaches. By offering a detailed classification of clinical studies and actionable perspectives, this review serves as a guideline for researchers and clinicians entering the field, providing a clear framework for addressing current challenges and advancing the potential of liquid biopsy biomarkers in ICI treatment.
논문정보
- Review Paper
- 2025년 05월 (BRIC 등록일 2025-05-07)
- 국내(교신)+국외 연구진
- 바이오·의료융합 > 바이오센싱 및 나노바이오물질
댓글 작성 로그인
팝업 닫기관련 링크
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
